SG11201809778TA - Dna antibody constructs for use against pseudomonas aeruginosa - Google Patents
Dna antibody constructs for use against pseudomonas aeruginosaInfo
- Publication number
- SG11201809778TA SG11201809778TA SG11201809778TA SG11201809778TA SG11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA SG 11201809778T A SG11201809778T A SG 11201809778TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pseudomonas aeruginosa
- pct
- subject
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332363P | 2016-05-05 | 2016-05-05 | |
PCT/US2017/031449 WO2017193101A1 (en) | 2016-05-05 | 2017-05-05 | Dna antibody constructs for use against pseudomonas aeruginosa |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809778TA true SG11201809778TA (en) | 2018-12-28 |
Family
ID=60203552
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809778TA SG11201809778TA (en) | 2016-05-05 | 2017-05-05 | Dna antibody constructs for use against pseudomonas aeruginosa |
SG10202011016WA SG10202011016WA (en) | 2016-05-05 | 2017-05-05 | Dna antibody constructs for use against pseudomonas aeruginosa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011016WA SG10202011016WA (en) | 2016-05-05 | 2017-05-05 | Dna antibody constructs for use against pseudomonas aeruginosa |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190153076A1 (pt) |
EP (1) | EP3452090A4 (pt) |
JP (2) | JP2019520085A (pt) |
KR (2) | KR20190025826A (pt) |
CN (1) | CN110072554A (pt) |
AU (2) | AU2017261374B2 (pt) |
BR (1) | BR112018072716A2 (pt) |
CA (1) | CA3023094A1 (pt) |
EA (1) | EA201892525A1 (pt) |
MX (1) | MX2018013525A (pt) |
SG (2) | SG11201809778TA (pt) |
WO (1) | WO2017193101A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57024B1 (sr) | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
MX2014005566A (es) * | 2011-11-07 | 2014-10-14 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
KR20200140799A (ko) * | 2018-01-31 | 2020-12-16 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물 |
EP4003333A4 (en) * | 2019-07-31 | 2023-11-01 | The Wistar Institute for Anatomy and Biology | MULTIVALENT DNA ANTIBODIES CONSTRUCTS AND THEIR USE |
WO2021022107A1 (en) * | 2019-07-31 | 2021-02-04 | The Wistar Institute Of Anatomy And Biology | Multivalent dna antibody constructs and use thereof |
CN118620074A (zh) * | 2020-06-01 | 2024-09-10 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008333985B2 (en) * | 2007-11-30 | 2015-02-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to the PcrV antigen of pseudomonas aeruginosa |
RS57024B1 (sr) * | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
RU2605390C2 (ru) * | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
WO2013036914A1 (en) * | 2011-09-08 | 2013-03-14 | University Of Florida Research Foundation, Inc. | Materials and methods for modulating immune responses |
US9580509B2 (en) * | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
MX2014005566A (es) * | 2011-11-07 | 2014-10-14 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
MX2014010495A (es) * | 2012-03-02 | 2014-11-14 | Ablynx Nv | Polipeptidos que enlazan a pcrv. |
WO2014074528A2 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
KR20150093834A (ko) * | 2012-12-13 | 2015-08-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Dna 항체 작제물 및 그 이용 방법 |
EP3080159A4 (en) * | 2013-12-13 | 2017-08-02 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
US20170183397A1 (en) * | 2014-05-05 | 2017-06-29 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
-
2017
- 2017-05-05 CN CN201780042016.0A patent/CN110072554A/zh active Pending
- 2017-05-05 KR KR1020187035163A patent/KR20190025826A/ko not_active IP Right Cessation
- 2017-05-05 MX MX2018013525A patent/MX2018013525A/es unknown
- 2017-05-05 JP JP2019510582A patent/JP2019520085A/ja active Pending
- 2017-05-05 KR KR1020237019235A patent/KR20230093338A/ko not_active Application Discontinuation
- 2017-05-05 CA CA3023094A patent/CA3023094A1/en active Pending
- 2017-05-05 US US16/098,908 patent/US20190153076A1/en active Pending
- 2017-05-05 AU AU2017261374A patent/AU2017261374B2/en active Active
- 2017-05-05 BR BR112018072716-4A patent/BR112018072716A2/pt unknown
- 2017-05-05 EP EP17793526.9A patent/EP3452090A4/en active Pending
- 2017-05-05 SG SG11201809778TA patent/SG11201809778TA/en unknown
- 2017-05-05 EA EA201892525A patent/EA201892525A1/ru unknown
- 2017-05-05 SG SG10202011016WA patent/SG10202011016WA/en unknown
- 2017-05-05 WO PCT/US2017/031449 patent/WO2017193101A1/en unknown
-
2023
- 2023-01-13 JP JP2023003954A patent/JP2023058497A/ja active Pending
-
2024
- 2024-06-04 AU AU2024203766A patent/AU2024203766A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017261374A1 (en) | 2018-12-20 |
CN110072554A (zh) | 2019-07-30 |
MX2018013525A (es) | 2019-06-10 |
WO2017193101A1 (en) | 2017-11-09 |
BR112018072716A2 (pt) | 2019-02-19 |
EP3452090A4 (en) | 2019-12-18 |
US20190153076A1 (en) | 2019-05-23 |
KR20230093338A (ko) | 2023-06-27 |
JP2019520085A (ja) | 2019-07-18 |
SG10202011016WA (en) | 2020-12-30 |
JP2023058497A (ja) | 2023-04-25 |
EA201892525A1 (ru) | 2019-04-30 |
KR20190025826A (ko) | 2019-03-12 |
AU2017261374B2 (en) | 2024-06-20 |
CA3023094A1 (en) | 2017-11-09 |
EP3452090A1 (en) | 2019-03-13 |
AU2024203766A1 (en) | 2024-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809778TA (en) | Dna antibody constructs for use against pseudomonas aeruginosa | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201804765UA (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201805048SA (en) | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia | |
SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |